Tudor Investment Corp ET AL Buys 33,098 Shares of Artivion, Inc. (NYSE:AORT)

Tudor Investment Corp ET AL increased its position in Artivion, Inc. (NYSE:AORT - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 177,062 shares of the company's stock after buying an additional 33,098 shares during the period. Tudor Investment Corp ET AL owned 0.42% of Artivion worth $5,062,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AORT. Barclays PLC grew its stake in Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company's stock valued at $1,888,000 after acquiring an additional 54,996 shares during the period. Lord Abbett & CO. LLC bought a new stake in Artivion during the 3rd quarter valued at $5,798,000. JPMorgan Chase & Co. increased its stake in Artivion by 394.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company's stock valued at $2,606,000 after purchasing an additional 78,120 shares in the last quarter. Calamos Advisors LLC raised its holdings in Artivion by 113.7% during the fourth quarter. Calamos Advisors LLC now owns 63,029 shares of the company's stock worth $1,802,000 after buying an additional 33,541 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Artivion by 21.8% in the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company's stock valued at $79,000 after buying an additional 497 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AORT has been the topic of a number of analyst reports. Stifel Nicolaus lowered their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Needham & Company LLC cut their target price on Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $31.40.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares of the company's stock, valued at $18,130,617.42. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,799 shares of company stock worth $2,356,223 in the last quarter. Insiders own 7.60% of the company's stock.

Artivion Stock Up 0.1 %

NYSE:AORT traded up $0.03 on Friday, hitting $23.36. The stock had a trading volume of 253,995 shares, compared to its average volume of 302,567. Artivion, Inc. has a 1 year low of $20.98 and a 1 year high of $32.33. The firm's fifty day simple moving average is $23.95 and its two-hundred day simple moving average is $27.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a market cap of $997.22 million, a P/E ratio of -1,168.00 and a beta of 1.65.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.